ES2282788T3 - Ligamiento quimico nativo en fase solida de peptidos no protegidos o protegidos en cisteinas n-terminales en disolucion acuosa. - Google Patents
Ligamiento quimico nativo en fase solida de peptidos no protegidos o protegidos en cisteinas n-terminales en disolucion acuosa. Download PDFInfo
- Publication number
- ES2282788T3 ES2282788T3 ES04029270T ES04029270T ES2282788T3 ES 2282788 T3 ES2282788 T3 ES 2282788T3 ES 04029270 T ES04029270 T ES 04029270T ES 04029270 T ES04029270 T ES 04029270T ES 2282788 T3 ES2282788 T3 ES 2282788T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- terminal
- solid phase
- segment
- resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 424
- 239000007790 solid phase Substances 0.000 title claims abstract description 185
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 55
- 239000000126 substance Substances 0.000 title description 49
- 238000009739 binding Methods 0.000 title description 21
- 230000027455 binding Effects 0.000 title description 18
- 238000004090 dissolution Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 54
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 79
- 210000004899 c-terminal region Anatomy 0.000 claims description 72
- 239000007787 solid Substances 0.000 claims description 52
- 150000007970 thio esters Chemical group 0.000 claims description 45
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 38
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 38
- 239000012071 phase Substances 0.000 claims description 38
- 235000018417 cysteine Nutrition 0.000 claims description 36
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 36
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 34
- 235000001014 amino acid Nutrition 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 24
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 21
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000004202 carbamide Substances 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 125000000524 functional group Chemical group 0.000 claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 150000003573 thiols Chemical class 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 52
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 abstract description 13
- 238000012544 monitoring process Methods 0.000 abstract description 8
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 239000007795 chemical reaction product Substances 0.000 abstract description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 124
- 229920005989 resin Polymers 0.000 description 120
- 239000011347 resin Substances 0.000 description 120
- 125000006850 spacer group Chemical group 0.000 description 62
- 238000004128 high performance liquid chromatography Methods 0.000 description 45
- 229960004198 guanidine Drugs 0.000 description 40
- 239000000047 product Substances 0.000 description 37
- 125000006239 protecting group Chemical group 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 27
- 229920001184 polypeptide Polymers 0.000 description 27
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000005859 coupling reaction Methods 0.000 description 22
- 238000000746 purification Methods 0.000 description 21
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 20
- 230000008878 coupling Effects 0.000 description 20
- 238000010168 coupling process Methods 0.000 description 20
- 239000002585 base Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 18
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 229930182817 methionine Natural products 0.000 description 18
- 238000003776 cleavage reaction Methods 0.000 description 17
- 230000007017 scission Effects 0.000 description 17
- -1 polyethylene Polymers 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 13
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- 238000009833 condensation Methods 0.000 description 10
- 230000005494 condensation Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 238000010647 peptide synthesis reaction Methods 0.000 description 9
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 8
- 230000002457 bidirectional effect Effects 0.000 description 8
- 230000008030 elimination Effects 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 101800001415 Bri23 peptide Proteins 0.000 description 7
- 102400000107 C-terminal peptide Human genes 0.000 description 7
- 101800000655 C-terminal peptide Proteins 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 7
- 238000010532 solid phase synthesis reaction Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000001012 protector Effects 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- CZGCBYXXDMGKNM-NSHDSACASA-N bis(2,2-dimethylpropyl) (2s)-2-aminopentanedioate Chemical compound CC(C)(C)COC(=O)CC[C@H](N)C(=O)OCC(C)(C)C CZGCBYXXDMGKNM-NSHDSACASA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 230000006340 racemization Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000006447 Phospholipases A2 Human genes 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 238000010612 desalination reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940040102 levulinic acid Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000012508 resin bead Substances 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- AIZZGGDXFGAYMR-IBGZPJMESA-N (2r)-3-(9h-fluoren-9-ylmethylsulfanyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2C(CSC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 AIZZGGDXFGAYMR-IBGZPJMESA-N 0.000 description 1
- HLCTYBOTPCIHTG-QMMMGPOBSA-N (2r)-3-(acetamidomethylsulfanyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(=O)NCSC[C@@H](C(O)=O)NC(=O)OC(C)(C)C HLCTYBOTPCIHTG-QMMMGPOBSA-N 0.000 description 1
- OQYBTXFHTQYWCZ-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(4-methylphenyl)methylsulfanyl]propanoic acid Chemical compound C1=CC(C)=CC=C1CSCC(C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 OQYBTXFHTQYWCZ-UHFFFAOYSA-N 0.000 description 1
- QBXODCKYUZNZCY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]oxyacetic acid Chemical compound CC(C)(C)OC(=O)NOCC(O)=O QBXODCKYUZNZCY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010078546 Complement C5a Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 101100421536 Danio rerio sim1a gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 101000950847 Homo sapiens Macrophage migration inhibitory factor Proteins 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000016776 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101100365794 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sim3 gene Proteins 0.000 description 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 description 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229910003910 SiCl4 Inorganic materials 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical class OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- QAVUAIFIABYJGI-UHFFFAOYSA-N diamino carbonate Chemical compound NOC(=O)ON QAVUAIFIABYJGI-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- FDNAPBUWERUEDA-UHFFFAOYSA-N silicon tetrachloride Chemical compound Cl[Si](Cl)(Cl)Cl FDNAPBUWERUEDA-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4955397P | 1997-06-13 | 1997-06-13 | |
| US49553P | 1997-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2282788T3 true ES2282788T3 (es) | 2007-10-16 |
Family
ID=21960431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04029270T Expired - Lifetime ES2282788T3 (es) | 1997-06-13 | 1998-06-12 | Ligamiento quimico nativo en fase solida de peptidos no protegidos o protegidos en cisteinas n-terminales en disolucion acuosa. |
| ES98929035T Expired - Lifetime ES2235336T3 (es) | 1997-06-13 | 1998-06-12 | Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98929035T Expired - Lifetime ES2235336T3 (es) | 1997-06-13 | 1998-06-12 | Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa. |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6326468B1 (https=) |
| EP (1) | EP1001968B1 (https=) |
| JP (1) | JP2002505672A (https=) |
| AT (2) | ATE354584T1 (https=) |
| AU (1) | AU745094B2 (https=) |
| CA (1) | CA2292724A1 (https=) |
| DE (2) | DE69828287T2 (https=) |
| ES (2) | ES2282788T3 (https=) |
| WO (1) | WO1998056807A1 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184344B1 (en) * | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US6849428B1 (en) * | 1997-03-05 | 2005-02-01 | New England Biolabs, Inc. | Intein-mediated protein ligation of expressed proteins |
| AU745094B2 (en) * | 1997-06-13 | 2002-03-14 | Gryphon Sciences | Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution |
| WO1999011655A1 (en) * | 1997-09-04 | 1999-03-11 | Gryphon Sciences | Modular protein libraries and methods of preparation |
| AUPP589598A0 (en) | 1998-09-14 | 1998-10-08 | University Of Queensland, The | Novel peptides |
| US7001745B1 (en) * | 1998-09-30 | 2006-02-21 | New England Biolabs, Inc. | Intein mediated peptide ligation |
| EP1159289A1 (en) * | 1999-03-11 | 2001-12-05 | Gryphon Sciences | Chemical synthesis and use of soluble membrane protein receptor domains |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US20040014082A1 (en) * | 2000-08-11 | 2004-01-22 | Invitrogen Corporation | Highly homogeneous molecular markers for electrophoresis |
| JP2004506221A (ja) * | 2000-08-11 | 2004-02-26 | インヴィトロジェン コーポレーション | 高度に均一な電気泳動用分子マーカー |
| KR20030046389A (ko) * | 2000-09-01 | 2003-06-12 | 그리폰 테라퓨틱스, 인코포레이티드 | 친핵체에 안정한 티오에스테르 발생 화합물, 제조 및 사용방법 |
| WO2002057293A2 (en) * | 2001-01-22 | 2002-07-25 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
| US7256275B2 (en) * | 2001-03-09 | 2007-08-14 | Boston Probes, Inc. | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation |
| GB0113657D0 (en) * | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7781488B2 (en) * | 2002-06-10 | 2010-08-24 | Amylin Pharmaceuticals, Inc. | Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation |
| JP2005531616A (ja) * | 2002-06-29 | 2005-10-20 | アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | イソフラボン濃縮物およびその製造法 |
| US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
| US8227411B2 (en) | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
| US7166574B2 (en) * | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
| US20040198958A1 (en) * | 2002-12-11 | 2004-10-07 | Ming-Qun Xu | Carrier-ligand fusions and uses thereof |
| EP1616003A4 (en) | 2002-12-30 | 2007-06-20 | Gryphon Therapeutics Inc | WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PL2298347T3 (pl) * | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
| WO2004105685A2 (en) * | 2003-05-22 | 2004-12-09 | Gryphon Therapeutics, Inc. | Displaceable linker solid phase chemical ligation |
| US7414028B1 (en) * | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
| US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
| US7528105B1 (en) | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
| US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
| US20080227696A1 (en) | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| JP4895826B2 (ja) * | 2004-02-20 | 2012-03-14 | バイオサーフェス エンジニアリング テクノロジーズ，インク． | 骨形成蛋白−２の正のモジュレーター |
| TWI351284B (en) | 2004-04-09 | 2011-11-01 | Chugai Pharmaceutical Co Ltd | Novel water-soluble prodrugs |
| US7872096B2 (en) * | 2004-05-24 | 2011-01-18 | Rigel Pharmaceuticals, Inc. | Methods for cyclizing synthetic polymers |
| CN102343084A (zh) | 2005-03-31 | 2012-02-08 | 安米林药品公司 | 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂 |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| WO2007100358A2 (en) * | 2005-10-07 | 2007-09-07 | University Of Chicago | Convergent synthesis of proteins by kinetically controlled ligation |
| US20090118271A1 (en) * | 2005-10-19 | 2009-05-07 | Chugai Seiyaku Kabushiki Kaisha | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug |
| US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
| JP2009541358A (ja) | 2006-06-22 | 2009-11-26 | バイオサーフェス エンジニアリング テクノロジーズ，インク． | 骨形成を強化するためにｂｍｐ−２増幅因子／共活性化因子を送達するための組成物および方法 |
| US8309522B2 (en) | 2007-02-05 | 2012-11-13 | Amylin Pharmaceuticals, Llc | Neuromedin and FN-38 peptides for treating psychiatric diseases |
| US8404804B2 (en) * | 2007-08-28 | 2013-03-26 | Ipsen Pharma S.A.S. | Methods and intermediates for chemical synthesis of polypeptides and proteins |
| EP2536287A4 (en) * | 2010-02-18 | 2015-10-07 | Advanced Proteome Therapeutics Inc | SPECIFIC SITE SIZE OF PROTEINS USING CHEMICAL MODIFICATION TO PROMOTE PROTEIN CONJUGATE FORMATION, PROTEIN DIMER FORMATION, AND AGRAFTED PEPTIDES |
| CA2812951A1 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Llc | Engineered polypeptides having enhanced duration of action |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| CN103957926B (zh) | 2011-07-08 | 2018-07-03 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| FR2981352B1 (fr) * | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | Procede de synthese de proteines |
| CA2873112A1 (en) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| WO2013177231A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| US11273176B2 (en) | 2016-03-02 | 2022-03-15 | The Brigham And Women's Hospital, Inc. | Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation |
| CN110382516B (zh) * | 2017-03-02 | 2022-11-08 | 株式会社糖锁工学研究所 | 氨基酸聚合物的制备方法 |
| WO2020070587A1 (en) | 2018-10-01 | 2020-04-09 | Université De Genève | Methods for producing a plurality of polypeptide variants suitable for biological analysis |
| WO2020110330A1 (ja) * | 2018-11-30 | 2020-06-04 | 株式会社糖鎖工学研究所 | ペプチドチオエステル、ペプチドの新規製造方法 |
| WO2021072306A1 (en) | 2019-10-10 | 2021-04-15 | 1859, Inc. | Methods and systems for microfluidic screening |
| WO2021077317A1 (zh) * | 2019-10-23 | 2021-04-29 | 烟台迈百瑞国际生物医药股份有限公司 | 一种寡肽连接子中间体及其制备方法 |
| WO2022266467A2 (en) | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Recombinant histone polypeptide and uses thereof |
| WO2024146707A1 (en) | 2023-01-06 | 2024-07-11 | Université De Genève | Variant ligand conjugates for payload delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5064940A (en) * | 1988-05-11 | 1991-11-12 | Protein Technologies, Inc. | Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis |
| US5101059A (en) * | 1989-12-05 | 1992-03-31 | Research Corporation Technologies, Inc. | Amino acid protecting groups |
| DK0832096T3 (da) | 1995-05-04 | 2001-10-01 | Scripps Research Inst | Syntese af proteiner ved nativ kemisk ligering |
| WO1998028434A1 (en) | 1996-12-24 | 1998-07-02 | The Scripps Research Institute | General chemical ligation |
| AU745094B2 (en) * | 1997-06-13 | 2002-03-14 | Gryphon Sciences | Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution |
| US6329468B1 (en) * | 2000-01-21 | 2001-12-11 | Bostik Findley, Inc. | Hot melt adhesive based on semicrystalline flexible polyolefins |
-
1998
- 1998-06-12 AU AU80695/98A patent/AU745094B2/en not_active Ceased
- 1998-06-12 AT AT04029270T patent/ATE354584T1/de not_active IP Right Cessation
- 1998-06-12 EP EP98929035A patent/EP1001968B1/en not_active Expired - Lifetime
- 1998-06-12 ES ES04029270T patent/ES2282788T3/es not_active Expired - Lifetime
- 1998-06-12 AT AT98929035T patent/ATE285415T1/de not_active IP Right Cessation
- 1998-06-12 JP JP50326799A patent/JP2002505672A/ja not_active Ceased
- 1998-06-12 WO PCT/US1998/012278 patent/WO1998056807A1/en not_active Ceased
- 1998-06-12 US US09/097,094 patent/US6326468B1/en not_active Expired - Fee Related
- 1998-06-12 DE DE69828287T patent/DE69828287T2/de not_active Expired - Fee Related
- 1998-06-12 DE DE69837170T patent/DE69837170T2/de not_active Expired - Fee Related
- 1998-06-12 CA CA002292724A patent/CA2292724A1/en not_active Abandoned
- 1998-06-12 ES ES98929035T patent/ES2235336T3/es not_active Expired - Lifetime
-
2001
- 2001-11-15 US US09/987,675 patent/US7030217B2/en not_active Expired - Fee Related
- 2001-11-15 US US09/987,655 patent/US7094871B2/en not_active Expired - Fee Related
-
2005
- 2005-05-03 US US11/119,831 patent/US20050209440A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69828287T2 (de) | 2005-12-15 |
| US7094871B2 (en) | 2006-08-22 |
| DE69837170D1 (de) | 2007-04-05 |
| ATE285415T1 (de) | 2005-01-15 |
| US20020132975A1 (en) | 2002-09-19 |
| CA2292724A1 (en) | 1998-12-17 |
| AU8069598A (en) | 1998-12-30 |
| ES2235336T3 (es) | 2005-07-01 |
| JP2002505672A (ja) | 2002-02-19 |
| ATE354584T1 (de) | 2007-03-15 |
| AU745094B2 (en) | 2002-03-14 |
| DE69828287D1 (de) | 2005-01-27 |
| WO1998056807A1 (en) | 1998-12-17 |
| US20050209440A1 (en) | 2005-09-22 |
| EP1001968B1 (en) | 2004-12-22 |
| EP1001968A1 (en) | 2000-05-24 |
| US7030217B2 (en) | 2006-04-18 |
| US6326468B1 (en) | 2001-12-04 |
| DE69837170T2 (de) | 2007-11-22 |
| US20020169282A1 (en) | 2002-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2282788T3 (es) | Ligamiento quimico nativo en fase solida de peptidos no protegidos o protegidos en cisteinas n-terminales en disolucion acuosa. | |
| Raibaut et al. | Solid phase protein chemical synthesis | |
| JP4327589B2 (ja) | ３つまたはそれ以上の成分を用いた改良された自然化学的連結 | |
| EP1115739B1 (en) | Auxiliary for amide bond formation | |
| Marinzi et al. | A new scaffold for amide ligation | |
| JP4399627B2 (ja) | ３つまたはそれ以上の成分による化学ペプチド連結 | |
| JP2001507027A (ja) | 一般的化学結合 | |
| US20040138412A1 (en) | Extended native chemical ligation | |
| EP1518862B1 (en) | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution | |
| EP1274722A2 (en) | Purification of polypeptides | |
| JP2010537984A (ja) | ポリペプチドおよび蛋白質の化学合成のための方法および中間体 | |
| JP2004508383A (ja) | 拡張天然型化学的ライゲーション | |
| AU768649B2 (en) | Auxiliary for amide bond formation | |
| AU2002300066B2 (en) | Process for Rapid Solution Synthesis of Peptides | |
| CN114008066A (zh) | 肽或蛋白质或拟肽的制造方法 | |
| JAMES et al. | Chemoselective and orthogonal ligation techniques | |
| AU2002363612A1 (en) | Extended native chemical ligation of three or more peptide fragments | |
| AU2002319850A1 (en) | Improved native chemical ligation with three or more components |